Intellia Therapeutics Inc buy Barclays PLC
Start price
28.02.25
/
50%
€9.82
Target price
28.02.26
€25.05
Performance (%)
-21.01%
Price
16.12.25
€7.76
Summary
This prediction is currently active. The price of Intellia Therapeutics Inc has decreased since the start of the prediction. Compared to the start price this results in a performance of -21.01%. This prediction currently runs until 28.02.26. The prediction end date can be changed by Barclays_PLC at any time. Barclays_PLC has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Intellia Therapeutics Inc | -3.048% | -3.048% |
| iShares Core DAX® | 0.060% | 1.215% |
| iShares Nasdaq 100 | -3.065% | -0.519% |
| iShares Nikkei 225® | -2.094% | -3.066% |
| iShares S&P 500 | -1.657% | -0.069% |
Comments by Barclays_PLC for this prediction
In the thread Intellia Therapeutics Inc diskutieren
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Barclays PLC from $55.00 to $26.00. They now have an "overweight" rating on the stock.
Ratings data for NTLA provided by MarketBeat
Stopped prediction by Barclays_PLC for Intellia Therapeutics Inc
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€8.12
07.11.25
07.11.25
€12.13
07.11.26
07.11.26
-4.43%
16.12.25
16.12.25
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€15.58
08.11.24
08.11.24
€51.38
08.11.25
08.11.25
-41.87%
09.11.25
09.11.25
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€36.00
04.08.23
04.08.23
€81.52
04.08.24
04.08.24
-40.22%
05.08.24
05.08.24